Arete Therapeutics Secures $13,300,000 Series A Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=786e6307-b077-4efe-bbbd-197236e29966&Preview=1 -
Date
5/23/2007 -
Company Name
Arete Therapeutics -
Mailing Address
7000 Shoreline Court South San Francisco, CA 94080 -
Company Description
Arête Therapeutics Inc. is discovering and developing ‘first in class’ small molecule drugs directed at novel targets for cardiovascular diseases and inflammation. The Company’s proprietary therapies are directed at a new branch of arachidonic acid metabolism, which is a proven (US $10+B) pathway for therapeutic intervention in a variety of inflammatory diseases. -
Website
http://www.aretetherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$13,300,000 -
Transaction Round
Series A -
Proceeds Purposes
Dinesh V. Patel, Ph.D.,president and chief executive officer of Arête Therapeutics Inc. said, “This financing, with anexceptional group of top tier investors, will allow us to advance our product portfolio andachieve clinical proof of concept in humans. We anticipate initiating clinical trials for our firstIND candidate, AR9281, by the end of 2007.” -
M&A Terms
-
Venture Investor
Frazier Healthcare Ventures -
Venture Investor
Alta Partners -
Venture Investor
Three Arch Partners -
Venture Investor
Burrill & Company -
Venture Investor
Altitude Capital Partners
